Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) — Market Cap & Net Worth
Market Cap & Net Worth: Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)
Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) has a market capitalization of $152.18 Million (Rs14.07 Billion) as of May 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #17588 globally and #911 in its home market, demonstrating a 5.11% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jagsonpal Pharmaceuticals Limited's stock price Rs210.37 by its total outstanding shares 66890450 (66.89 Million). Analyse Jagsonpal Pharmaceuticals Limited cash flow conversion to see how efficiently the company converts income to cash.
Jagsonpal Pharmaceuticals Limited Market Cap History: 2015 to 2026
Jagsonpal Pharmaceuticals Limited's market capitalization history from 2015 to 2026. Data shows growth from $32.44 Million to $152.18 Million (19.02% CAGR).
Jagsonpal Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jagsonpal Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Jagsonpal Pharmaceuticals Limited's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.25x
Jagsonpal Pharmaceuticals Limited's market cap is 0.25 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $22.67 Million | $1.43 Billion | $32.54 Million | 0.02x | 0.70x |
| 2017 | $25.45 Million | $1.44 Billion | $118.65 Million | 0.02x | 0.21x |
| 2018 | $20.97 Million | $1.27 Billion | -$115.51 Million | 0.02x | N/A |
| 2019 | $17.39 Million | $1.67 Billion | $72.16 Million | 0.01x | 0.24x |
| 2020 | $49.07 Million | $1.59 Billion | $78.71 Million | 0.03x | 0.62x |
| 2021 | $126.47 Million | $1.88 Billion | $170.58 Million | 0.07x | 0.74x |
| 2022 | $263.51 Million | $2.18 Billion | $188.55 Million | 0.12x | 1.40x |
| 2023 | $277.96 Million | $2.37 Billion | $267.21 Million | 0.12x | 1.04x |
| 2024 | $441.89 Million | $2.09 Billion | $224.63 Million | 0.21x | 1.97x |
| 2025 | $139.33 Million | $2.69 Billion | $553.61 Million | 0.05x | 0.25x |
Competitor Companies of JAGSNPHARM by Market Capitalization
Companies near Jagsonpal Pharmaceuticals Limited in the global market cap rankings as of May 4, 2026.
Key companies related to Jagsonpal Pharmaceuticals Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Jagsonpal Pharmaceuticals Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Jagsonpal Pharmaceuticals Limited's market cap moved from $32.44 Million to $ 152.18 Million, with a yearly change of 19.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs152.18 Million | +9.22% |
| 2025 | Rs139.33 Million | -68.47% |
| 2024 | Rs441.89 Million | +58.98% |
| 2023 | Rs277.96 Million | +5.48% |
| 2022 | Rs263.51 Million | +108.36% |
| 2021 | Rs126.47 Million | +157.71% |
| 2020 | Rs49.07 Million | +182.15% |
| 2019 | Rs17.39 Million | -17.06% |
| 2018 | Rs20.97 Million | -17.58% |
| 2017 | Rs25.45 Million | +12.22% |
| 2016 | Rs22.67 Million | -30.11% |
| 2015 | Rs32.44 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Jagsonpal Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $152.18 Million USD |
| MoneyControl | $152.18 Million USD |
| MarketWatch | $152.18 Million USD |
| marketcap.company | $152.18 Million USD |
| Reuters | $152.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more